| Literature DB >> 27823897 |
A Mascolo1, M Sessa2, C Scavone2, A De Angelis2, C Vitale3, L Berrino2, F Rossi2, G Rosano4, A Capuano2.
Abstract
It is commonly accepted that the renin-angiotensin-aldosterone system (RAAS) is a cardiovascular circulating hormonal system that plays also an important role in the modulation of several patterns in the brain. The pathway of the RAAS can be divided into two classes: the traditional pathway of RAAS, also named classic RAAS, and the non-classic RAAS. Both pathways play a role in both cardiovascular and neurological diseases through a peripheral or central control. In this regard, renewed interest is growing in the last years for the consideration that the brain RAAS could represent a new important therapeutic target to regulate not only the blood pressure via central nervous control, but also neurological diseases. However, the development of compounds able to cross the blood-brain barrier and to act on the brain RAAS is challenging, especially if the metabolic stability and the half-life are taken into consideration. To date, two drug classes (aminopeptidase type A inhibitors and angiotensin IV analogues) acting on the brain RAAS are in development in pre-clinical or clinical stages. In this article, we will present an overview of the biological functions played by peripheral and brain classic and non-classic pathways of the RAAS in several clinical conditions, focusing on the brain RAAS and on the new pharmacological targets of the RAAS.Entities:
Keywords: Angiotensin; Coronary artery disease; Heart failure; Neurological diseases; Pharmacology; Renin–angiotensin–aldosterone system
Mesh:
Substances:
Year: 2016 PMID: 27823897 DOI: 10.1016/j.ijcard.2016.10.069
Source DB: PubMed Journal: Int J Cardiol ISSN: 0167-5273 Impact factor: 4.164